Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 969 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 0.9% Sodium Chloride Injection Clear all
Terminated Phase 1 Interventional Results available

Multiple Dose Study Of PF-05231023 In Obese Adult Subjects

NCT01923389
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Placebo, 100 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling

NCT01740817
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Intralipid 20%, Saline
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Sep 23, 2026, 2:19 PM EDT
Terminated Phase 4 Interventional Results available

US Guided GNB vs Saline Injection for TKA

NCT03316118
View directory record Official record
Conditions
Postoperative Pain, Total Knee Arthroplasty, Nerve Block
Interventions
bupivacaine, saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Not applicable Interventional Results available

Short-Term Application of Tocilizumab Following Myocardial Infarction

NCT02419937
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Keesler Air Force Base Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Keesler Air Force Base, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Not applicable Interventional Results available

Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction

NCT01542502
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

NCT04463251
View directory record Official record
Conditions
Acute ST Segment Elevation Myocardial Infarction
Interventions
RPH-104 80 mg, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Cleveland, Ohio • Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2024 · Synced Sep 23, 2026, 2:19 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

NCT07675629
View directory record Official record
Conditions
HIV Prevention
Interventions
PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Trial of NanoPac Intratumoral Injection in Lung Cancer

NCT04314895
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer, Lung Cancer, Small Cell, Neoplasm of Lung
Interventions
NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Drug
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Gainesville, Florida • Fort Wayne, Indiana • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin A to Treat Arm Tremor

NCT02207946
View directory record Official record
Conditions
Essential Tremor of the Upper Limbs
Interventions
IncobotulinumtoxinA, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

NCT05698095
View directory record Official record
Conditions
Pharmacokinetics, Safety, Tolerability
Interventions
5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo
Drug
Lead sponsor
Usona Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 23, 2026, 2:19 PM EDT
Terminated Phase 2 Interventional Results available

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

NCT03146403
View directory record Official record
Conditions
Genital Herpes, HSV-2 Infection
Interventions
GEN-003, Matrix-M2, 0.9% normal saline
Biological · Other
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee

NCT01221441
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
TissueGene-C, Normal Saline
Biological · Drug
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Pinellas Park, Florida • Baltimore, Maryland • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 4 Interventional Results available

Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity

NCT03096288
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Evolocumab, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Sep 23, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional Results available

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT04478994
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
TEPEZZA, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

NCT04623086
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin Degludec, Insulin Glargine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Not applicable Interventional Results available

Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?

NCT02276495
View directory record Official record
Conditions
Pain Management
Interventions
ACB Control - 20 ml saline injection for ACB, ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block, Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Other · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 23, 2026, 2:19 PM EDT
Recruiting Phase 4 Interventional

The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery

NCT06450392
View directory record Official record
Conditions
Orbital Edema, Orbital Ecchymosis
Interventions
Tranexamic acid injection, Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML), normal saline - injection, normal saline - intravenous
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 23, 2026, 2:19 PM EDT
Not listed Phase 2 Interventional

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease

NCT00606164
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bryostatin for Injection, Placebo
Drug
Lead sponsor
Blanchette Rockefeller Neurosciences Insitute
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2008 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

NCT01264783
View directory record Official record
Conditions
Myocardial Infarct
Interventions
RNS60, Placebo
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Precision Dosing of Alemtuzumab

NCT03302754
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation
Interventions
Alemtuzumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Weeks to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

NCT04761822
View directory record Official record
Conditions
SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
Interventions
Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years and older
Enrollment
746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

NCT04347239
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebo, Leronlimab (700mg)
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Alexander City, Alabama • Fullerton, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 23, 2026, 2:19 PM EDT